AbCellera Biologics, Inc. ABCL 深 滬
等待開盤 10-22 09:30:00 美东时间
5.58
-0.280
-4.78%
華盛通- 最 高5.8531
- 今 開5.80
- 成交量 426.24万股
- 最 低 5.56
- 昨 收 5.86
- 總市值 16.63亿
- 52周最高 6.515
- 市盈率 靜 --
- 換手率 1.43%
- 52周最低 1.8906
- 委 比 -61.47%
- 總股本 2.98亿
- 歷史最高 71.91
- 量 比 0.85
- 振 幅 5.00%
- 歷史最低 1.8906
- 每 手 1
- 風險率 1.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Stock Market Today: Dow Futures Slip, Nasdaq Rises Amid Mixed Trade—AngioDynamics, Entero Therapeutics, Fermi In Focus
U.S. stock futures were fluctuating on Thursday following Wednesday's record advances. Futures of major benchmark indices were mixed.
10-02 17:50
Bentley Systems Surges 7% In Pre-Market: What's Driving The Rally?
BSY stock jumps to $56.00 after revealing third-quarter 2025 earnings webcast details, building on Wednesday's gains.
10-02 17:42
Why Is Super Micro Computer Stock Trending Tonight?
Super Micro Computer Inc. saw a 9.30% jump in its stock price, finishing at $52.40 in after-hours trading, marking its third consecutive day of gains, while outperforming other key tech companies like HP and Intel.
10-02 15:37
Why Did AbCellera's Stock Jump Over 7% After Hours?
AbCellera's stock rose 7.72% in after-hours trading following an 18.49% gain during regular trading, with a strong performance expected in Q3 earnings.
10-02 14:15
AbbVie Presents Phase 2 Data On Epcoritamab For Relapsed/Refractory DLBCL Showing Manageable Safety Profile
Data presented at 13th Society of Hematologic Oncology (SOHO) Annual MeetingNORTH CHICAGO, Ill., Sept. 3, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced updated results from the Phase 2 EPCORE® NHL-6 trial
09-03 20:38
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
08-19 01:35
Expert Outlook: AbCellera Biologics Through The Eyes Of 4 Analysts
4 analysts have expressed a variety of opinions on AbCellera Biologics (NASDAQ:...
08-09 02:02
Stifel Maintains Buy on AbCellera Biologics, Lowers Price Target to $7
Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and lowers the price target from $8 to $7.
08-08 21:41
AbCellera Biologics Q2 EPS $(0.12) Beats $(0.15) Estimate, Sales $17.084M Beat $5.824M Estimate
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 21.05 percent. This is a 7.69 percent increase over losses of $(0.13) per share
08-08 04:33
